Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatinKroonen, M. Y. A. M., Stevens, J., de Zeeuw, D. & Heerspink, H. J. L., 30-Sep-2019, In : Diabetes obesity & metabolism. 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
AIM: The PLANET trials showed that atorvastatin 80 mg but not rosuvastatin at either 10 or 40 mg reduced urinary protein to creatinine ratio (UPCR) at similar effects on LDL-cholesterol. However, individual changes in both UPCR and LDL-cholesterol during treatment with these statins varied widely between patients. This inter-individual variability could not be explained by patients' physical or biochemical characteristics. We assessed whether the plasma concentrations of both statins were associated with LDL-cholesterol and UPCR response.
MATERIALS AND METHODS: The PLANET trials randomized patients with a UPCR of 500-5000 mg/g and fasting LDL-cholesterol >2.33 mmol/l to a 52-week treatment with atorvastatin 80 mg, rosuvastatin 10 mg or 40 mg. For the current analysis, patients with available samples at week 52 and treatment compliance >80% by pill count were included (N = 295). The main outcome measurements were percentage change in UPCR and absolute change in LDL-cholesterol (delta LDL) from baseline to week 52.
RESULTS: Median (interquartile range) plasma concentration at week 52 for atorvastatin 80 mg was 3.9 ng/ml (IQR: 2.1 to 8.7), for rosuvastatin 10 mg 1.0 ng/ml (IQR: 0.7 to 2.0) and for rosuvastatin 40 mg 3.5 ng/ml (IQR: 2.0 to 6.8). Higher plasma concentration of statin was associated with larger LDL-cholesterol reductions at week 52 [rosuvastatin r = -0.40 (P < 0.001); atorvastatin r = -0.28 (P = 0.006)]. The plasma concentration of both statins did not correlate with UPCR change [rosuvastatin r = 0.07 (P = 0.30); atorvastatin r = 0.16 (P = 0.13)].
CONCLUSIONS: Individual variation in plasma concentrations of rosuvastatin and atorvastatin was associated with LDL-cholesterol changes in patients. The individual variation in UPCR change was not associated with the plasma concentration of both statins. This article is protected by copyright. All rights reserved.
|Number of pages||8|
|Journal||Diabetes obesity & metabolism|
|Publication status||Published - 30-Sep-2019|